


# Enteric coated granules for improved enzyme delivery in cystic fibrosis



**creon<sup>®</sup>**  
pancreatin

Capule dissolves in stomach

Granules unaffected by stomach acid

Enzymes released in duodenum

Mimics the normal digestive process

## A predictable release for cystic fibrosis patients

**PRESCRIBING INFORMATION:** Presentation: Brown/yellow capsules containing enteric coated granules of pancreatin equivalent to: 9,000 BP units of amylase; 8,000 BP units of lipase; 210 BP units of protease. Available in packs of 100. Basic N.H.S. price £13.33. Indication: Pancreatic exocrine insufficiency. Dosage and administration: Adults and children: Initially one or two capsules with meals, then adjust according to response. The capsules should be swallowed whole, or for ease of administration they may be opened and the granules taken with fluid or soft food, but without chewing. If the granules are mixed with food, it is important that they are taken immediately, otherwise dissolution of the enteric coating may result. Contra-indications, Warnings, etc. Contra-indications: Substitution with pancreatic enzymes is contra-indicated in the early stages of acute pancreatitis. Warnings: Use in pregnancy: There is inadequate evidence of safety in use during pregnancy. The product is of porcine origin. Rarely, cases of hyper-uricosuria and hyper-uricaemia have been reported with high doses of pancreatin. Overdosage could precipitate meconium ileus equivalent. Perianal irritation could occur, and, rarely, inflammation when large doses are used. Product Licence Number: 5727/0001. Name and address of Licence Holder Kali Chemie Pharma GmbH, Postfach 220, D-3000, Hannover 1, West Germany.

**duphar**

Further information is available from:

Duphar Laboratories Ltd, Duphar House, Gaters Hill, West End, Southampton SO3 3JD. Tel: (0703) 472281

## **THE HEINZ FELLOWSHIPS OF THE BRITISH PAEDIATRIC ASSOCIATION**

H. J. Heinz Company Limited generously endows Fellowships in Paediatrics which are administered by the British Paediatric Association.

Two or three Fellowships will be offered each year, the number and type awarded in any one year depending on circumstances and the calibre of applicants available.

The types of Fellowship, which are open to men or women are

A To enable paediatricians from any part of the Commonwealth overseas to spend up to twelve weeks in the United Kingdom, meeting British Paediatricians and seeing something of their work. Preference will be given to those recently established in an academic career who can arrange their visit to allow attendance at the Annual Meeting of the British Paediatric Association in April 1990.

C To enable paediatricians from the United Kingdom of Registrar, Senior Registrar, or Consultant status, or non-medically qualified members of the Association, in the early years of professional life to make a short working visit (up to three months) to a centre in a developing country, teaching or conducting research so as to benefit both fellow and hosts.

Applications for A Fellowships must be received by the British Paediatric Association not later than 31st December 1988

Applications for C Fellowships can be accepted by 31st January 1989 or 31st July 1989.

The conditions for the Fellowships and applications forms may be obtained from the British Paediatric Association, 5 St Andrew's Place, Regent's Park, London NW1 4LB.



1921



1922



1975



1982



# Insulin with a future

In 1922, Lilly led the world in insulin technology when their co-operation with Banting and Best resulted in the first large scale production of insulin.

Lilly is still the world's largest manufacturer of insulin.

Lilly was the first to manufacture insulin by genetic engineering—  
technology which assures  
future supplies of insulin.

**Humulin**  
Human Insulin (prb)

The first genetically engineered human insulin

# What would you feed her if

## The Challenge

This question is one of the biggest challenges in

neonatology today. It is the question of how to

provide the best possible nutrition for the

preterm infant. The answer is not simple

because the preterm infant is a very

vulnerable patient. The challenge is to

provide the best possible nutrition for the

preterm infant. The answer is not simple

because the preterm infant is a very

vulnerable patient. The challenge is to

provide the best possible nutrition for the

preterm infant. The answer is not simple

because the preterm infant is a very

vulnerable patient. The challenge is to

provide the best possible nutrition for the

preterm infant. The answer is not simple

because the preterm infant is a very

vulnerable patient. The challenge is to

provide the best possible nutrition for the

preterm infant. The answer is not simple

because the preterm infant is a very

vulnerable patient. The challenge is to

provide the best possible nutrition for the

preterm infant. The answer is not simple

because the preterm infant is a very

vulnerable patient. The challenge is to

provide the best possible nutrition for the

preterm infant. The answer is not simple

because the preterm infant is a very

vulnerable patient. The challenge is to

provide the best possible nutrition for the

preterm infant. The answer is not simple

because the preterm infant is a very

vulnerable patient. The challenge is to

provide the best possible nutrition for the

preterm infant. The answer is not simple

because the preterm infant is a very

vulnerable patient. The challenge is to

provide the best possible nutrition for the

preterm infant. The answer is not simple

because the preterm infant is a very

vulnerable patient. The challenge is to

provide the best possible nutrition for the

preterm infant. The answer is not simple

because the preterm infant is a very

vulnerable patient. The challenge is to

provide the best possible nutrition for the

preterm infant. The answer is not simple

because the preterm infant is a very

vulnerable patient. The challenge is to

provide the best possible nutrition for the

preterm infant. The answer is not simple

because the preterm infant is a very

vulnerable patient. The challenge is to

## References

1. Committee on Nutrition of the preterm infant. European Society of Paediatric Gastroenterology and Nutrition. Nutrition and feeding of preterm infants. Oxford: Blackwell, 1987.
2. ESPGAN Committee on Nutrition of the Preterm Infant. Scand. 1987 Suppl 336: 1-14.
3. Salle, B., Putet G., Service de Neonatologie de L'Hopital Edouard Herriot, Lyon, France. Senterre J., Rigo, J., Neonatologie de L'Hopital Universitaire de Baviere, Liege.

Milupa Ltd., Milupa House, Uxbridge Road, Hillingdon

01-475 7000

# she were born premature?

## ESPGAN - Sets New Standards in Preterm Nutrition

A comprehensive review<sup>1</sup> and Guidelines<sup>2</sup> on nutrition and feeding of preterm infants have recently been published by the European Society of Paediatric Gastroenterology and Nutrition (ESPGAN).

## New Milupa Prematil – Meets ESPGAN Guidelines for Preterm Formulae

Developed to incorporate recent advances


Milupa Prematil meets the ESPGAN Guidelines and translates them into action.

## New Milupa Prematil – Proven Performance in clinical trials<sup>3,4</sup>

- ★ High fat absorption (87%) ensures energy retention and enhances protein utilization.<sup>3</sup>
- ★ Excellent protein utilization (90%) promotes growth without metabolic overload.<sup>3</sup>
- ★ Good tolerance and nutritional balance ensures supplementation is rarely required.<sup>4†</sup>

**NEW** milupa  
**Prematil**®

Milupa Prematil® an assured path to normal formula feeding.









The BMJ's new series of books of general interest by medical writers

**Not Always on the Level** by E J Moran Campbell. Romantic memories of a Yorkshire childhood; hilarious ones of student days in London; a detailed and fascinating account of Campbell's pioneering work in respiratory physiology; and a painfully honest description of what it is like to a manic depressive.

Price: Inland £14.95; Abroad £18.50; USA \$30.00  
BMA members: Inland £13.95; Abroad £17.50; USA \$28.00

**Recollections and Reflections** by Douglas Black, who recalls episodes from his remarkable career—in which he has been professor of medicine at Manchester University, chief scientist at the DHSS, and president of the Royal College of Physicians—and reflects on the practice and progress of medicine, university teaching and administration, public service, and life in general.

Price: Inland £14.95; Abroad £17.50; USA \$29.00  
BMA members: Inland £13.95; Abroad £16.50; USA \$27.00

**Doctors in Science and Society** by Christopher Booth, who examines the lives and times of some eighteenth century medical scientists and the role of their present day successors. A must for anyone interested in the past and future of medical science.

Price: Inland £14.95; Abroad £19.50; USA \$32.00  
BMA members: Inland £13.95; Abroad £18.50; USA \$30.00

All prices include postage, by air abroad  
Please enclose payment with order

ORDER FROM: British Medical Journal  
PO Box 295, London WC1H 9TE  
or any leading medical bookseller

## Newcastle-upon-Tyne SYMPOSIA IN CHILD HEALTH

No. 7—Perspectives in Paediatric Infection and Immunity

Friday, 9th and Saturday, 10th September 1988  
in The Medical School, Newcastle-upon-Tyne

**Topics to include:**

Herpes group viruses and the infant—Professor C. Peckham, London  
Antimicrobial policies in the nursery—Dr D. Isaacs, Oxford  
Kawasaki disease—Dr M. Dillon, London  
Respiratory virus diagnosis—Dr C. Taylor, Newcastle-upon-Tyne  
Epstein-Barr virus infection—Dr A. G. Bird, Newcastle-upon-Tyne  
Immunisation—controversies and future policies—Dr E. Ross, London  
Therapeutic strategies in virus infection—Dr T. Rogers, London  
Non-respiratory tuberculosis—Dr J. A. Innes, East Birmingham  
Bacterial meningitis—Dr H. Smithy, London  
Recurrent infection—Dr M. Haeney, Manchester  
Clinicopathological conference—Dr M. Dillon, London

Registration fee: £20 (includes coffee, tea and lunch).

For further details please contact:  
Mrs P McEwen, Department of Child Health,  
The Medical School, University of Newcastle-upon-Tyne,  
Framlington Place, Newcastle-upon-Tyne, NE2 4HH.  
Telephone: 091 232 8511 Ext. 78731

This meeting is sponsored by  
Wyeth Department of Postgraduate Education

# BMJ BOOKS

For a complete  
Catalogue of BMJ  
Books

Please write to:  
BRITISH MEDICAL JOURNAL,  
P.O. Box 295,  
London, WC1H 9TE

HUMAN VELOSULIN® (Neutral Insulin Injection, human insulin (emp)), HUMAN INSULATARD® (Isophane Insulin Injection (NPH), human insulin (emp)), HUMAN MIXTARD® 30/70 (Insulin Suspension comprising 30% Neutral Insulin Injection and 70% Isophane Insulin Injection (NPH), human insulin (emp)), HUMAN INITARD® 50/50 (Neutral Suspension comprising 50% Neutral Insulin Injection (NPH), human insulin (emp)), HUMAN VELOSULIN, HUMAN INSULATARD, HUMAN MIXTARD 30/70 and HUMAN INITARD 50/50 are available in 10 ml vials containing 100 i.u./ml. To aid identification the metal sealing rings of the vials have tactile marks as follows: Human Velosulin – one mark; Human Insulatard – two marks; Human Mixtard 30/70 – three marks; Human Initard 50/50 – four marks. The vials are fitted with tamper-evident caps. **Uses** The treatment of insulin-requiring diabetes. **Dosage and Administration** The dosage of insulin is determined by the physician according to the needs of the patient. Human Velosulin may be given by s.c., i.m., or i.v. injection. Human Insulatard, Human Mixtard 30/70 and Human Initard 50/50 should be given by s.c. injection several times before being given by s.c. or i.m. injection (they must not be given intravenously). Inter-mixing does not affect the characteristics of any of these insulins. **Use in pregnancy** Human insulin requirements usually fall during the first trimester and increase during the second and third trimesters. **Use in the elderly:** Insulin may have a more prolonged action due to reduced clearance. **Contra-indications warnings etc. Contra-indications:** Hypoglycaemia. **Precautions:** Patients transferring from other insulins may require a dosage adjustment. Concomitant therapy with oral contraceptives, diuretics, beta blockers and M.A.O.I.s may affect insulin requirements. **Side and Adverse Effects:** Hypoglycaemia. Local reactions, lipodystrophy and hypokalaemia are rarely reported with human insulins. **Pharmaceutical Precautions** used. **Legal Category P. Package Quantities** 10 ml glass vials. **Basic NHS Price** Human Insulatard 3132/0034; Human Mixtard 30/70 3132/0037; Human Initard 50/50 3132/0021; Human Velosulin 3132/0012; Human Mixtard 30/70 0003/0213; Human Initard 50/50 0003/0214. **Use:** Garland Court, Garland Road, East Grinstead, West Sussex RH19 1DN. **Manufactured by:** Wellcome Foundation Ltd, Crewe Hall, Crewe, Cheshire CW1 1UB. Tel: Crewe (0270) 583151.



Store between 2–8°C, protected from sunlight. Insulin which has been frozen should be discarded. **Product Licence Numbers** NORDISK-UK: Human Velosulin 3132/0040. THE WELLCOME FOUNDATION LTD: Human Velosulin 0003K. Further information is available on request from either: Nordisk-L, Tel: East Grinstead (0342) 410373, or Wellcome Medical Division. **Reference** I. Heine R.J. et al. Diabetologia, 1984; 27; 558-562. \*Registered



# HUMAN VELOSULIN®

Human neutral soluble insulin (emp)

# HUMAN INSULATARD®

Human isophane (NPH) insulin (emp)

Quick and intermediate acting insulins developed to be compatible  
 No interaction when mixed!




# NOCTURNAL ENURESIS?



## Dry nights start with **DESMOSPRAY**<sup>®</sup> DESMOPRESSIN NASAL SPRAY

### The new physiological approach to Nocturnal Enuresis

Recent information indicates that bedwetters with primary nocturnal enuresis may produce excessive volumes of urine overnight owing to inadequate nocturnal levels of vasopressin (antidiuretic hormone). DESMOSPRAY at bedtime can correct this overnight polyuria, by supplementing the patients' own ADH with DESMOPRESSIN, the established vasopressin analogue with enhanced antidiuretic activity. DESMOSPRAY sprayed into each nostril at bedtime is usually sufficient to control bedwetting in this large group of sufferers, leading to dry nights.



#### ABRIDGED PRESCRIBING INFORMATION

**Presentation:** Metered dose pre-compression atomiser delivering 10 micrograms Desmopressin per spray. **Uses:** Desmopressin is a structural analogue of the natural antidiuretic hormone vasopressin, with increased antidiuretic activity and prolonged duration of action. The pressor activity is greatly reduced as a result of which side-effects are rarely seen. **INDICATIONS and DOSAGE:** Primary Nocturnal Enuresis Adults and children from 5 years of age: one spray in each nostril (20 micrograms) at bedtime. The dose may be increased up to 2 sprays in each nostril (40 micrograms) if the lower dose is not sufficiently effective. The treatment should not be prescribed for more than 28 days. **Treatment of Diabetes Insipidus:** The average maintenance dose in adults and children is one or two sprays (10 to 20 micrograms) once or twice daily. **Contra-indications:** When used to control Primary Nocturnal Enuresis DESMOSPRAY should only be used in patients with normal blood pressure. **Precautions:** DESMOSPRAY should be used with caution in pregnant patients although the oxytocic effect is very low. Care should be taken with patients who have reduced renal function and/or cardiovascular disease. Fluid overload should be avoided and patients should only take as much fluid as required to satisfy thirst. **Legal category:** POM **Package quantity:** 5 ml bottle **Basic N.H.S. Price:** £19.92 PL No. 3194/0024 PL Holder: Ferring Pharmaceuticals Ltd. 11 Mount Road, Feltham, Middlesex TW13 6JG. DESMOSPRAY is a trademark.

Further information is available and should be consulted before prescribing - Ferring Pharmaceuticals Ltd, 11 Mount Road, Feltham, Middlesex TW13 6JG

**FERRING**  
PHARMACEUTICALS

# Health Visitor

The journal of the Health Visitors' Association



**Health Visitor**, published monthly, is the Official Journal of the Health Visitors' Association, which is the professional organisation of the health visiting profession in the United Kingdom. The primary object of the profession is to promote health in all its aspects. Health visitors are state registered nurses, have a midwifery or obstetric qualification and have completed a further year of health visiting training. They have chosen to use their knowledge and experience of illness and accident to enable them better to fulfil their role in promoting health and to detect early deviations from the normal.

The editorial content of **Health Visitor** reflects the varied interests and concerns of those engaged in preventive medicine and nursing in the community, with contributions from a wide variety of disciplines involved in the problems of community-based medical care.

**Recent and future topics include:**

- Caring for the Health of Young Children • The Effect on Health of the Unemployed • Drug and Solvent Abuse in Young People • Overheating of Young Babies • Screening Tests for Hearing and Visual Impairment in Children • Child Abuse • Encopresis and Enuresis • Behavioural and Sleeping Problems • Immunisation and Vaccination • Health Needs of Ethnic Minorities • Sudden Infant Death • Scoliosis in Infants and Children • Sickle Cell Anaemia.

*Annual Subscription (1988): UK & Eire £29.00; Abroad £49.00; USA \$76.00*  
including postage, by air speeded despatch abroad

---

**ORDER FORM**

Professional & Scientific Publications, Tavistock House East,  
Tavistock Square, London WC1H 9JR, England

*Please enter my subscription to **Health Visitor***

I enclose .....  
Please make remittances payable to Professional & Scientific Publications. Overseas orders: sterling payments must be on a London Bank, dollar payments on a bank in the United States of America.

or please charge this order to my:

ACCESS / MASTERCARD     BARCLAYCARD/VISA (please tick as applicable)



CARD NUMBER

EXPIRY DATE..... SIGNATURE .....

NAME ..... (BLOCK LETTERS PLEASE)

ADDRESS .....

POSTAL CODE .....

*When Only  
The Best is  
Good Enough in  
Neonatal Care*

S&W manufacture and market a wide range of high quality technical products for use in the acute care areas of medicine.

For full details of all our products contact us at the address below.

**S&W**

Care for everybody.

S&W  
Ruxley Corner,  
Sidcup,  
Kent DA14 5BL  
Telephone: 01-309 0433.  
Telex: 896328  
Fax: 01-309 0919

**The pioneers of pediatric medicine**  
449

*Review*

**Wiedemann-Beckwith syndrome**  
W. Engström, S. Lindham, P. Schofield  
450

*Annotation*

**Antibody deficiency – ubiquitous problem or useless concept?**  
R. L. Wasserman 458

*Original investigations*

**Preterm or small-for-gestational-age infants. Neurological and behavioural development at the age of 6 years**  
M. Hadders-Algra, H. J. Huisjes, B. C. L. Touwen 460

**Prenatal and postnatal factors affecting short-term survival of very low birth weight infants**  
Italian Collaborative Group on Preterm Delivery 468

**The second nation-wide survey in Japan of vitamin K deficiency in infancy**  
Y. Hanawa, M. Maki, B. Murata, E. Matsuyama, Y. Yamamoto, T. Nagao, K. Yamada, I. Ikeda, T. Terao, S. Mikami, K. Shiraki, M. Komazawa, A. Shirahata, Y. Tsuji, K. Motohara, I. Tsukimoto, K. Sawada 472

**Low biotinidase activity in plasma of some preterm infants: possible source of false-positive screening results**  
T. Suormala, H. Wick, E. R. Baumgartner 478

**Effects of prolonged versus acute indomethacin therapy in very low birth-weight infants with patent ductus arteriosus**  
P. G. Rhodes, M. G. Ferguson, N. S. Reddy, J. A. Joransen, J. Gibson 481

**Plasma and right auricle concentrations of atrial natriuretic polypeptide in children with cardiac diseases**  
K. Akimoto, A. Miyata, K. Kangawa, H. Matsuo, Y. Koga, Y. Matsuoka, K. Hayakawa 485

**Glucocorticoid receptors in mononuclear blood cells and their correlation to endogenous and exogenous corticoids in healthy and asthmatic children**  
M. Griese, G. Kusenbach, K. Lüsebring, W. Köster, B. Roth, D. Reinhardt 490

**The DiGeorge syndrome. I. Clinical evaluation and course of partial and complete forms of the syndrome**  
W. Müller, H. H. Peter, M. Wilken, H. Jüppner, H. C. Kalfelz, H. P. Krohn, K. Miller, C. H. L. Rieger 496

**Clonal variation in childhood acute lymphoblastic leukaemia at early and late relapse detected by analyses of phenotype and genotype**  
A. Raghavachar, W.-D. Ludwig, C. R. Bartram 503

**The EEG in early diagnosis of the Angelman (Happy Puppet) syndrome**  
S. G. Boyd, A. Harden, M. A. Patton 508

*Short communications*

**Treatment of unresectable hepatoblastoma with cisplatin, vincristin and 5-fluorouracil**  
T. Herlin, K. Norup, K. Storm 514

**C7 deficiency and persistent haematuria**  
T. Sakano, T. Hamasaki, M. Mori, T. Ohta, K. Ueda, K. Ishigame, M. Kawamura, N. Takeda 516

**Infantile cortical hyperostosis associated with the Wiskott-Aldrich syndrome**  
M. Abinun, M. Mikuška, B. Filipović 518

**Neonatal brucellosis**  
M. M. Lubani, K. I. Dudin, D. C. Sharda, N. M. Abu Sinna, T. Al-Shab, A. A. Al-Refe'ai, S. M. Labani, A. Nasrallah 520

**Problems encountered using temazepam syrup for sedation in infants**  
C. O'Callaghan, A. D. Milner, A. Swarbrick 523

**On the efficacy of various irradiation regimens in phototherapy of neonatal hyperbilirubinaemia**  
P. Eggert, C. Stick, S. Swalve 525

*Case reports*

**4-Hydroxybutyric aciduria in a patient without ataxia or convulsions**  
K. M. Gibson, G. Hoffmann, W. L. Nyhan, S. Aramaki, J. A. Thompson, S. I. Goodman, D. A. Johnson, R. R. Fife 529

**Male pseudohermaphroditism due to 5 $\alpha$ -reductase deficiency in a Swedish family**  
S.-A. Ivarsson, M. Damkjaer Nielsen, T. Lindberg 532

**Multiple associated endocrine abnormalities in a patient with pseudohypoparathyroidism type 1a**  
M. Shima, O. Nose, K. Shimizu, Y. Seino, H. Yabuuchi, T. Saito 536

**Martolf syndrome in a brother and sister: clinical features and pattern of inheritance**  
R. C. M. Hennekam, A. G. van de Meeberg, J. M. van Doorne, P. F. Dijkstra, J. B. Bijlsma 539

**Serpentine fibula – polycystic kidney syndrome. A variant of the Melnick-Needles syndrome or a distinct entity?**  
G. U. Exner 544

**Osteoglophonic dysplasia: a new case**  
H. Santos, P. Campos, R. Alves, A. Torrado 547

**Multiple Pterygium Syndrome type Escobar in two brothers. Follow-up data from childhood to adulthood**  
J. P. Fryns, P. Volcke, H. van den Berghe 550

**Intra-abdominal cystic lymphangioma in a newborn infant. Case report and review of the literature**  
L. P. Brion, J. P. Goolaerts, E. R. Avni, D. Ardichvili, M. Tondeur 553

**Ventricular septal defect with overriding aorta in trisomy-18**  
R. J. Moene, M. Sobotka-Plojhar, A. Oppenheimer-Dekker, D. Lindhout 556

*Letters to the editors*

**Primary or secondary cardiomyopathies?**  
A. A. Schmaltz 558

**Reply**  
A. Kohlschütter, G. Hausdorf 558

Indexed in *Current Contents*



Springer International

**Subscription information**

Volume 147 (6 issues) will appear in 1988. Information about obtaining back volumes and microform editions available upon request.

**North America.** Annual subscription rate: approx. US \$ 659.00 (single issue price approx. \$ 131.00), including carriage charges. Subscriptions are entered with prepayment only.

Orders should be addressed to:

Springer-Verlag New York Inc.  
Service Center Secaucus  
44 Hartz Way  
Secaucus, NJ 07094, USA  
Tel. (201) 348-4033  
Telex 023125994

**All other countries.** Annual subscription rate: DM 1158.00 plus carriage charges; Federal Republic of Germany: DM 17.98 incl. value added tax; all other countries: DM 40.80 ex-

cept for the following countries to which SAL delivery (Surface Airmail Lifted) is mandatory: Japan DM 71.40, India DM 57.60, Australia/New Zealand DM 78.60. Airmail delivery to all other countries is available upon request. Volume price: DM 1158.00, single issue price: DM 231.60 plus carriage charges. Subscriptions can either be placed via a bookdealer or sent directly to:

Springer-Verlag  
Heidelberger Platz 3, D-1000 Berlin 33  
Tel. (0)30/82 07-0, Telex 183319

# Monatsschrift Kinder- heilkunde

Organ der  
Deutschen Gesellschaft  
für Kinderheilkunde

136. Band  
Heft 7  
Juli 1988

Springer-Verlag  
Berlin Heidelberg New York London  
Paris Tokyo

	Thema des Monats Pädiatrie in der Dritten Welt	This Month's Topic Paediatrics in the Third World	339
H. J. Bremer, H. Wolf			
V. Köhler	Pädiatrie in der Dritten Welt	Paediatrics in the Third World	341
P. O. Abiodun, H. Wolf	Primäre Gesundheitsversorgung (Primary Health Care): Realität oder Utopie in einem Entwicklungsland?	Primary Health Care: Is it a Realistic Possibility in the Third World?	343
J. H. H. Ehrich, M. El Sheikh, E. Doehring, M. Dittrich, H. Wolf	Pädiatrische Forschung in den Tropen: Pro und Kontra	Paediatric Research in the Tropics: Pros and Cons	348
D. Nabarro	Ernährungsprobleme in Entwicklungsländern: Prioritäten für den Kinderarzt	Problems of Nutrition in Third World Countries: Priorities for Paediatricians	352
C. Oepen	Die Problematik medizinischer Hilfsprogramme für Kinder in der Sahel-Zone Afrikas: Beispiel Burkina Faso	The Problems of Medical Programmes Aimed at Helping Children in the Sahel-Region of Africa, Taking Burkina Faso as an Example	356
	<b>Pädiatrie aktuell</b>	<b>Trends in Paediatrics</b>	<b>360</b>
	<b>Was hat das Kind?</b>	<b>What's Wrong with the Child?</b>	
	<b>Trainingsprogramm für die Weiterbildung zum Kinderarzt</b>	<b>Program for Continuing Education of Paediatricians</b>	<b>361</b>
	<b>Aus Klinik und Forschung Originalien</b>	<b>Clinic and Research Originals</b>	
D. Lang, W. Engelhardt, G. von Bernuth	Verlauf der Myokarditis im Kindesalter	Follow-up Study of Acute Myocarditis in Children	362
F. Reiterer, R. Schenkeli, R. Kurz, R. Haidmayer	Effekt einer Aminophyllintherapie beim reif- geborenen Säugling mit Schlafapnoesyndrom	Effect of Aminophyllin in Full-term Infants with Idiopathic Sleep Apnea Syndrome	368
H. Rebmann, J. Hub, R. Huenges, A. Neu, D. Grunert, H. Horn, G. Döller, P. C. Döller, H.-J. Gerth, H. E. Wichmann, S. Klug	Prospektive epidemiologische Einjahres- längsschnittstudie über Luftschadstoffe und Krupp-Häufigkeit	Prospective Epidemiologic One-Year-Longitudinal- Investigation on Air-Pollution and Frequency of Croup	372
M. Teufel, H. Meyer-Hohnloser, E. M. Mörcke, U. Stubig, K. H. Niessen	Nachuntersuchungen bei 60 Kindern mit Colitis ulcerosa und Morbus Crohn	Follow-up Study in 60 Children with Ulcerative Colitis and Crohn's Disease	378
	<b>Der Interessante Fall</b>	<b>Interesting Cases</b>	
J. Kraus	Penisagenesie, persistierende Kloake und anorektale Agenesie	Penile Agensis, Persistent Cloaca and Imperforate Anus	384
M. Millner, K. W. Hausegger, G. Leitner	Chronische Gangstörung infolge einer pigmen- tierten villonodulären Synovitis an der Fußsohle	Pigmented Villonodular Synovitis of the Sole Causing a Chronic Gait Disturbance	387
S. Kotthoff, G. Eigster, I. Naib, J. Vogt	Lungensequester als Ursache einer akuten kardinalen Dekompensation bei einem 3 Wochen alten Neugeborenen	Congestive Heart Failure in a Neonate Caused by Bronchopulmonary Sequestration	390
R. Roscher, G. Gaedicke, W. Mohr	Mesenteriale Fibromatose im Kindesalter	Mesenterial Fibromatosis in Childhood	393
K. E. v. Mühlendahl	Becken- und Femoralvenenthrombosen im Kindesalter	Iliacal and Femoral Vein Thrombosis in Children	397
	<b>Wußten Sie schon? Aus der Praxis — für die Praxis</b>	<b>Do You Know? Practical Tips for Practitioners</b>	
H. Moll	Arzneimittel-Schnellinformation des Bundesgesundheitsamtes	Federal German Health Service Information on Drugs	400
	Auflösung und Kommentar des Trainings- programms für die Weiterbildung zum Kinderarzt	Solution and Commentary in the Program for Continuing Education of Paediatricians	399
	<b>Neue Bücher</b>	<b>New Books</b>	<b>400</b>
	<b>Tagesgeschichte, Personalia</b>	<b>News of the Day, Personal News</b>	<b>401</b>
	<b>Tegungskalender</b>	<b>Forthcoming Meetings</b>	<b>402</b>
	Zusammenfassungen der Vorträge der 18. Jahrestagung der Arbeitsgemeinschaft für Pädiatrische Nephrologie vom 10.—12. März 1988 in Hannover		403
	<b>Für die Dokumentation</b>	<b>Documentation</b>	<b>A 38/39</b>

Indexed in Current Contents

Monatsschr Kinderheilkd (1988) 136, 7

**Annual subscription: DM 298,- plus postage**

#### Indications

Epilepsy (generalised tonic-clonic and partial seizures).

#### Dosage in epilepsy

Use a gradually increasing dosage scheme, adjusting to the patient's needs. Adults: 100–200mg once or twice daily, increasing slowly up to 800–1200mg daily; in some cases 1600mg daily may be necessary. Children: up to 1 year old, 100–200mg daily; aged 1–5 years, 200–400mg daily; aged 5–10

years, 400–600mg daily; aged 10–15 years, 600–1000mg daily. It may be helpful to monitor drug levels: the optimum therapeutic range is 3–10µg/ml (13–42µmol/l).

#### Side-effects

Dizziness and diplopia (usually dose dependent), less frequently dry mouth, diarrhoea, nausea, vomiting. Generalised erythematous rash, disappearing on cessation of therapy.

Isolated reports of oedema, hyponatraemia, exfoliative dermatitis, leucopenia, thrombocytopenia, agranulocytosis, aplastic anaemia, cholestatic jaundice and acute renal failure. Blood count should be checked in early stages of treatment.

#### Precautions

Caution in patients taking oral anticoagulants or requiring oral contraception. In

pregnancy, potential benefits of Tegretol must be weighed against potential hazards. Do not administer with, or within two weeks of cessation of, MAOI therapy. Macrolide antibiotics (e.g. erythromycin) and isoniazid may elevate carbamazepine levels. In rats treated with carbamazepine for two years, incidence of liver tumours increased (no evidence of significant

bearing on the therapeutic use of the drug). Serum folic acid levels should be observed during anticonvulsant therapy.

#### Contra-indications

Previous drug sensitivity to Tegretol. Do not administer to patient with atrioventricular conduction abnormalities unless paced.

#### Packs

Tablets of 100mg (PL0001/5027) basic NHS price

£3.10 per 100, £14.93 per 500; tablets of 200mg (PL0001/5028) £5.76 per 100, £27.75 per 500; tablets of 400mg (PL0001/0088) £11.32 per 100; liquid 100mg/5ml (PL0001/0050) £5.53 per 300ml bottle. \* denotes registered trade mark. Full prescribing information is available from Geigy Pharmaceuticals, Horsham, West Sussex.



# TEGRETOL®

carbamazepine BP

After seizure control there's a lot of living to do

Geigy